ImmunityBio, Inc. IBRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$854.6M-109% | -$351.47M+15.0% | -$348.69M+40.7% | -$367.17M+38.6% | -$409.18M+32.0% | ||
| $16.08M-4.5% | $15.53M-11.6% | $15.8M-12.1% | $16.3M-10.0% | $16.83M-8.5% | ||
| $35.44M-0.7% | $36.81M+6.9% | $37.1M-2.8% | $35.71M-20.9% | $35.7M-23.3% | ||
| -$294.39M+20.5% | -$304.94M+22.1% | -$319.7M+24.1% | -$349.56M+14.7% | -$370.16M+4.9% | ||
| $4.5M-33.3% | $3.85M-44.2% | $5.05M-60.3% | $7.11M-54.5% | $6.75M-71.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | $0— | ||
| $625.15M+131% | $400.24M+42.1% | $452.28M+20.5% | $294.34M-50.7% | $270.42M-45.0% | ||
| —— | —— | —— | —— | —— | ||
| -$298.89M+20.7% | -$308.78M+22.4% | -$324.76M+25.2% | -$356.66M+16.2% | -$376.91M+8.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ImmunityBio, Inc. generate?
- ImmunityBio, Inc. (IBRX) generated -$294.4M in operating cash flow over the trailing twelve months.
- What is ImmunityBio, Inc.'s free cash flow?
- After $4.5M of capital expenditures, ImmunityBio, Inc.'s free cash flow was -$298.9M over the trailing twelve months, up 20.7% year over year.
- Where does ImmunityBio, Inc.'s cash flow data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
